|
Fig. 5 The Ena/VASP-EVH1 inhibitor reduces PANC-1 cell metastasis in vivo. (A) Mouse pharmacokinetics of the Ena/VASP-EVH1 inhibitor comparing subcutaneous (s.c) injection (dots) with the implantation of an osmotic pump (triangle). Analysis was performed in triplicates, and plasma concentrations are given as mean ± SD. Area under the curve (AUC) and maximal plasma concentration (Cmax) were calculated. (B) Average animal body weight of xenograft mouse experiment. Ena/VASP-EVH1 inhibitor (pink) and vehicle (gray) treated animals with s.c. application. (C) Metastasis scores of xenograft mouse experiment with orthotopically implanted PANC-1 cells. Animals were treated with the Ena/VASP-EVH1 inhibitor (pink) or vehicle (gray) with s.c. application. Metastasis score was determined ex vivo after the termination of all animals and represents the sum of all found metastasis in mm2 visible on the surface of the liver, lung, and spleen. Statistical significance (*P ≤ 0.05) was evaluated using the Mann–Whitney test.